Cost-Effectiveness of Umeclidinium/Vilanterol Versus Indacaterol/Glycopyrronium in Symptomatic patients with COPD in the UK

被引：0

作者：

Ismaila, Afisi S. ^{[1
]}

Shah, Dhvani ^{[2
]}

Martin, Alan ^{[3
]}

Kendall, Robyn ^{[4
]}

Noorduyn, Stephen ^{[5
]}

Dasari, Priyadarsini ^{[6
]}

Risebrough, Nancy A. ^{[7
]}

Compton, Chris ^{[8
]}

Noorduyn, Stephen G.

Risebrough, Nancy A. ^{[7
]}

Compton, Chris ^{[8
]}

Noorduyn, Stephen G.

机构：

[1] GSK, Value Evidence & Outcomes, Collegeville, PA USA

[2] ICON Plc, ICON Hlth Econ, Bridgewater, NJ USA

[3] GSK, Value Evidence & Outcomes, Brentford, England

[4] ICON Plc, ICON Hlth Econ, Vancouver, BC, Canada

[5] GSK, Value Evidence & Outcomes, Mississauga, ON, Canada

[6] ICON Plc, ICON Hlth Econ, Houston, TX USA

[7] ICON Plc, ICON Hlth Econ, Burlington, ON, Canada

[8] GSK, R&D Global Med, Brentford, England

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

基金：

芬兰科学院;

关键词：

D O I：

10.1183/13993003.congress-2023.PA1328

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[21] Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Shah, Dhvani
Driessen, Maurice
Risebrough, Nancy
Baker, Timothy
Naya, Ian
Briggs, Andrew
Ismaila, Afisi S.
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
[22] Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Dhvani Shah
Maurice Driessen
Nancy Risebrough
Timothy Baker
Ian Naya
Andrew Briggs
Afisi S. Ismaila
Cost Effectiveness and Resource Allocation, 16
[23] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
Maltais, Francois
Bjermer, Leif
Kerwin, Edward M.
Jones, Paul W.
Watkins, Michael L.
Tombs, Lee
Naya, Ian P.
Boucot, Isabelle H.
Lipson, David A.
Compton, Chris
Vahdati-Bolouri, Mitra
Vogelmeier, Claus F.
RESPIRATORY RESEARCH, 2019, 20 (01) : 238
[24] Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
Driessen, Maurice
Shah, Dhvani
Risebrough, Nancy
Baker, Timothy
Naya, Ian
Briggs, Andrew
Ismaila, Afisi S.
RESPIRATORY MEDICINE, 2018, 145 : 130 - 137
[25] COST-EFFECTIVENESS OF TIOTROPIUM VERSUS GLYCOPYRRONIUM IN MODERATE TO VERY SEVERE COPD IN FRANCE
Eklund, O.
Borgstrom, F.
Lindh, M.
Detournay, B.
Setton, M.
Le Lay, K.
VALUE IN HEALTH, 2016, 19 (07) : A555 - A555
[26] COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK
Shah, D.
Driessen, M.
Risebrough, N.
Baker, T. M.
Naya, I
Lloyd, E. J.
Briggs, A.
Ismaila, A.
VALUE IN HEALTH, 2017, 20 (05) : A202 - A202
[27] Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe COPD in France
Eklund, Oskar
Borgstrom, Fredrik
Lindh, Maria
Laurendeau, Caroline
Detournay, Bruno
Luciani, Laura
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[28] COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL
Tozato, C.
Suzuki, C.
VALUE IN HEALTH, 2018, 21 : S411 - S411
[29] COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION INDACATEROL/GLYCOPYRRONIUM VS. TIOTROPIUM AND SALMETEROL/FLUTICASONE IN THE MANAGEMENT OF COPD IN GREECE
Geitona, M.
Kousoulakou, H.
Kalogeropoulou, M.
Mitsiki, E.
Panitti, E.
Steiropoulos, P.
VALUE IN HEALTH, 2015, 18 (07) : A500 - A500
[30] COST-EFFECTIVENESS ANALYSIS OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG VERSUS TIOTROPIUM/OLODATEROL 5/5 MCG IN SYMPTOMATIC PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
Driessen, M.
Whalen, J.
Buguth, Seewoodharry B.
Vallejo-Aparicio, L. A.
Naya, I
Asukai, Y.
Alcazar-Navarrete, B.
Miravitlles, M.
Garcia-Rio, F.
Risebrough, N.
VALUE IN HEALTH, 2018, 21 : S233 - S233

← 1 2 3 4 5 →